This new capability will result from a joint private-public investment made by Biovectra and the federal and provincial governments who are contributing CDN 39.8m and CDN 10m respectively to the total project cost of CDN 79.6m in support of the Biovectra mRNA Vaccine and Bio-manufacturing facility.
Biovectra CEO Oliver Technow was joined earlier TODAY at the company's Charlottetown headquarters by the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry and the Honourable Dennis King, Premier of Prince Edward Island to announce support for this new domestic capability.
Over the past several years, Biovectra has expanded its business to develop and produce commercial scale biotherapeutics, at its accredited facility in Windsor, Nova Scotia.
It is one of five Biovectra sites, located in Atlantic Canada.
As part of this most recent investment, the Windsor site will also see an expansion to support the development and production of plasmid DNA, the key ingredient to manufacture mRNA therapeutics and vaccines.
The PEI bio-manufacturing facility will include fill finish capabilities.
Biovectra is a global biotech and pharmaceutical CDMO (contract development and manufacturing organization) that specializes in clinical-to-commercial scale production capabilities for: biologics, bioreagents, fermented small molecules, synthetic small molecules, and active pharmaceutical ingredients.
Flexibility, creativity, process optimization and compliance are at the heart of our method.
With over 550 employees and cGMP facilities in Prince Edward Island and Nova Scotia, Canada we assure our programs advance on time and with the highest quality outcomes.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine